Testing EGFR with Idylla on Cytological Specimens of Lung Cancer: A Review

International Journal of Molecular Sciences

Alessandro Caputo¹  Francesco Sabbatino¹  Angela D’Ardia¹  Pio Zeppa¹  Caterina Picariello²  Chiara Ciaparrone²  Antonio D’Antonio² 

[1] Department of Medicine and Surgery, University of Salerno, 84081 Salerno, Italy;Department of Pathology, University Hospital “San Giovanni di Dio e Ruggi D’Aragona”, 84125 Salerno, Italy;

关键词: idylla;    cytology;    cytopathology;    epidermal growth factor receptor;    lung cancer;    lung adenocarcinoma;   

DOI  :  10.3390/ijms22094852

来源: DOAJ

【 摘 要 】

The current standard of care for advanced non-small-cell lung cancer is based on detecting actionable mutations that can benefit from targeted therapy. Comprehensive genetic tests can have long turn-around times, and because EGFR mutations are the most prevalent actionable mutation, a quick detection would enable a prompt initiation of targeted therapy. Furthermore, the scarcity of diagnostic material means that sometimes only cytologic material is available. The Idylla™ EGFR assay is a real-time PCR–based method able to detect 51 EGFR mutations in 2.5 h. Idylla is validated for use only on FFPE sections, but some researchers described their experiences with cytological material. We reviewed the relevant literature, finding four articles describing 471 cases and many types of cytological input material: smears, cell-block sections, suspensions, and extracted DNA. The sensitivity, specificity, and limit of detection appear comparable to those obtained with histological input material, with one exception: the usage of scraped stained smears as input may reduce the accuracy of the test. In conclusion, usage of cytological material as input to the Idylla EGFR test is possible. A workflow where common mutations are tested first and fast, leaving rarer mutations for subsequent comprehensive profiling, seems the most effective approach.

【 授权许可】

Unknown